Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.

Lupi, Alessandro; Bona, Roberta Della; Meliga, Emanuele; Capodanno, Davide; Schaffer, Alon; Bongo, Angelo S; Gaudio, Giovanni; Guasti, Luigina; Alexopoulos, Dimitrios; Valgimigli, Marco; Porto, Italo (2018). Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. Thrombosis and haemostasis, 118(5), pp. 852-863. Schattauer 10.1055/s-0038-1635578

[img] Text
2018 Thromb Haemost_Lupi.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (297kB) | Request a copy

BACKGROUND  Early escalation from clopidogrel to new generation P2Y12 inhibitors is common practice in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Real-world data about this strategy, however, are limited. METHODS  From 2012 to 2015, 1,057 consecutive STEMI patients treated with pPCI in an Italian hub-and-spoke network were prospectively included in an observational registry (RENOVAMI, ClinicalTrials.gov Identifier: NCT01760382). We compared the prevalence, predictive factors and in-hospital outcomes of patients escalated to a new generation P2Y12 inhibitor within the first 24 hours from pPCI with those continuing on admission antiplatelet therapy. RESULTS  In the first 24 hours after pPCI, 165 patients (15.6%) were escalated from clopidogrel to a new generation P2Y12 inhibitor, while de-escalation to clopidogrel was occasional (19 patients, 1.8%) and switch between new generation P2Y12 inhibitors was rare (8 patients, 0.8%, all from ticagrelor to prasugrel). Drug eluting stent use (adjusted odds ratio [OR], 2.19, 95% confidence interval [CI], 1.55-3.08,  = 0.0002) and impaired renal function (adjusted OR, 0.19, 95% CI, 0.05-0.77,  = 0.02) were the only independent predictive factors for the decision to escalate. After adjustment for potential confounders, escalation did not predict in-hospital outcomes, whereas the overall use of new generation P2Y12 inhibitors was correlated with a better in-hospital survival (adjusted hazard ratio, 0.47, 95% CI, 0.25-0.91,  = 0.03). Moreover, escalation did not influence bleeding rates. CONCLUSIONS  In this prospective registry of STEMI patients treated with pPCI and contemporary antiplatelet therapy, early escalation to a new generation P2Y12 inhibitor appeared safe and did not significantly affect in-hospital bleeding rates.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Valgimigli, Marco

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0340-6245

Publisher:

Schattauer

Language:

English

Submitter:

Amanda Valle

Date Deposited:

03 Aug 2018 13:04

Last Modified:

03 Aug 2018 13:04

Publisher DOI:

10.1055/s-0038-1635578

PubMed ID:

29618159

BORIS DOI:

10.7892/boris.119041

URI:

https://boris.unibe.ch/id/eprint/119041

Actions (login required)

Edit item Edit item
Provide Feedback